Most Recent
The NSW Supreme Court has approved a $44.25 million settlement of two class actions against the trustees of failed debenture issuer Provident Capital, including $12.8 million in legal fees for Slater and Gordon and $4.3 million for funder Litman Holdings.
Liquidators for the collapsed Hastie Group will pursue test cases against two construction companies in their legal fight against more than two dozen major builders over tens of millions of dollars in unpaid bills, but an application is looming to halt the proceedings pending the outcome of a High Court challenge.
Bannister Law has withdrawn from a class action it filed against Ford over allegedly defective Powershift transmissions following a dispute between the firm and the litigation funder that's backing the case.
Generic drug company Apotex has settled a patent infringement case brought by global pharmaceutical giant Lundbeck over its blockbuster antidepressant Lexapro.
AFT Pharmaceuticals breached the consumer laws with misleading ads over the strength of its painkiller Maxigesic, a judge has found, siding with rival drug maker Reckitt Benckiser.
The Commonwealth of Australia has resolved its claims against pharmaceutical giant Wyeth over the price it paid to list Effexor on the PBS, months after a high stakes trial wrapped up.
US tyre company Goodyear has dropped its challenge to a mixed trade mark ruling in its long-running dispute with UK-based rival Dunlop over coveted trade marks for 'Dunlop' and 'Flying D'.
A unit of Fortescue Metals Group has won its bid for emails between Squire Patton Boggs and a unit of electricity provider TransAlta Energy relating to a disputed power purchase agreement, saying privilege was waived when the emails were forwarded to a third party.
A Federal Court judge has expressed her disbelief at a cross claim by generic drug maker Sandoz against Danish multinational H Lundbeck, as the court begins to weigh arguments over damages owed to Lundbeck in the long-running patent case over its blockbuster anti-depressant Lexapro.
Preparations for a December trial between Merck Sharp & Dohme Corporation and Wyeth over four patents for the pneumococcal disease vaccine are underway, and a panel of experts will feature prominently in the high-stakes hearing over the world's best-selling vaccine.